BCY LifeSciences

Bicycle Therapeutics is a clinical-stage biopharmaceutical company pioneering a novel class of medicines called Bicycles®. These are short, synthetic peptides constrained by a small molecule scaffold into two loops, combining the high affinity and specificity of antibodies with the small size and tissue penetration of small molecules. The company's lead programs include Bicycle Toxin Conjugates (BTCs) such as BT8009, targeting Nectin-4, and BT5528, targeting EphA2, which are currently in clinical trials for various solid tumors. Bicycle is also developing a pipeline of "Bicycle-targeted innate immune activators" and has established significant strategic collaborations with major pharmaceutical companies including Novartis, Bayer, and Roche.